NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Royalty Pharma plc (RPRX) Stock Analysis

Royalty Pharma plc (RPRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

RPRX

$63.96

+$0.08 (+0.13%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RPRX with… →

RPRX Key Statistics

As of Sep 4, 2026
Trading
Open
$63.55
Previous Close
$63.88
Day's Range
63.43–64.38
52-Week Range
34.08–64.38
Volume
3.40M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.43
Valuation
Market Cap
$36.96B
P/E Ratio
34.39
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
11.15
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.49
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
14.57
EPS (ttm)Profit attributable to each share over the last twelve months.
1.86
Financials (FY)
Revenue (FY)
$2.38B+5.06%
Net Income (FY)
$770.95M−10.25%
Profit marginThe share of revenue left as profit after all costs and taxes.
32.02%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
445.28M
1-Year Return
+75.99%
Dividend and dates
Dividend
$0.94+1.47%
Ex-Dividend Date
August 14, 2026
Earnings Date
November 4, 2026estimated
Avg Volume
3.01M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RPRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+67.13%
2025+55.29%
2024−6.36%
2023−27.08%
2022+0.99%
2021−19.09%
2020 (partial year)+13.33%

As of September 4, 2026.

RPRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.38B$770.95M32.4%
2024$2.26B$858.98M37.9%
2023$2.35B$1.13B48.2%
2022$2.24B$42.83M1.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.38B—$1.56B$770.95M32.4%
2024$2.26B—$1.29B$858.98M37.9%
2023$2.35B—$1.49B$1.13B48.2%
2022$2.24B—$922.89M$42.83M1.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RPRX Dividend History

$0.88+4.8% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$0.713—
2025$0.884+4.8%
2024$0.844+5.0%
2023$0.804+5.3%
YearDividends per sharePaymentsChange
2026 (partial year)$0.713—
2025$0.884+4.8%
2024$0.844+5.0%
2023$0.804+5.3%
2022$0.764+11.8%
2021$0.684+126.7%
2020$0.302—

Most recent payment: $0.24 per share, ex-dividend August 14, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

RPRX Valuation vs Biotechnology Median

Median of 656 stocks
MetricRPRXBiotechnology medianvs median
P/E34.3912.57174% above
P/S ratio14.5715.265% below
Profit margin32.02%0.00%32.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 18 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Royalty Pharma plc (RPRX) at $36.96B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 100.

The most recent close on file for RPRX is $63.96, dated September 4, 2026. That is +$0.08 (+0.13%) against the previous close. The 52-week range on file runs from $34.08 to $64.38. The latest close sits 87.67% above that 52-week low.

Financial Health

In fiscal 2025, Royalty Pharma plc reported revenue of $2.38B. That is +5.06% against the prior fiscal year, when revenue was $2.26B. The same year closed with net income of $770.95M. That is −10.25% against the prior fiscal year. The reported profit margin is 32.02%. That is 32 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 1.86.

Across the 4 fiscal years on file, revenue moves from $2.24B in 2022 to $2.38B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

RPRX trades at a trailing price-to-earnings ratio of 34.39. That is 173.59% above the Biotechnology median of 12.57. On forward earnings the ratio is 11.15. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.49. The price-to-sales ratio is 14.57. On price-to-sales that is 4.52% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 0.43. Annualized volatility over the trailing 6 years is 25.66%. Over the trailing twelve months the price has returned +75.99%. Measured over 5 years, that is +12.74% a year compounded.

Growth & Income

Shareholders receive a dividend, yielding 1.47% on the latest price. The indicated annual rate is $0.94 a share. The ex-dividend date on file is August 14, 2026. Dividends are recorded for 7 calendar years; 2026 shows 3 payments totalling $0.71 a share. The year before, 2025, totalled $0.88 a share.

The strongest complete calendar year on file is 2025 at +55.29%; the weakest is 2023 at −27.08%. Of the 5 complete calendar years on file, 2 finished higher. 2026 is still running; the price is +67.13% year to date.

Peer Comparison

Royalty Pharma plc (RPRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Royalty Pharma plc RPRX $36.96B 34.4
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Royalty Pharma plc trades at a P/E of 34.4.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Visit website →